Ligand Pharmaceuticals Inc. closed its acquisition of privately held Crystal Bioscience Inc. for an initial consideration of about $25 million in cash.
Crystal is now a wholly owned subsidiary of Ligand.
According to the merger agreement, Crystal shareholders will also receive up to $10.5 million in milestone payments and revenue sharing from existing licensees for a defined period.